US2008085868A1PendingUtilityA1

Monoclonal Antibody 3F1H10 Neutralising VHSV (Viral Haemorrhagic Septicaemia Virus)

52
Individually held — no corporate assignee on recordPriority: Sep 20, 1999Filed: Jul 27, 2007Published: Apr 10, 2008
Est. expirySep 20, 2019(expired)· nominal 20-yr term from priority
Inventors:Christopher John SecombesCharles CunninghamNiels Lorenzen
A61K 2039/505C07K 16/08C07K 2317/622A61P 31/00A61P 37/08
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a non-infectious nucleic acid (RNA and DNA) construct constructed to express a recombinant antibody or antibody fragment in a host cell. The antibody molecule confers protection to the host against a pathogen, allergen or toxin. The host may be any animal including a human.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for protection of an animal against a disease-causing agent, the composition comprising a non-infectious nucleic acid construct encoding a recombinant antibody to that agent.  
     
     
         2 . A pharmaceutical composition according to  claim 1  wherein the animal is selected from a mammal or a fish.  
     
     
         3 . A pharmaceutical composition according to  claim 1  wherein the animal has a deficient immune system.  
     
     
         4 . A pharmaceutical composition according to  claim 1  wherein the disease-causing agent is selected from a pathogen, an allergen or a toxic substance.  
     
     
         5 . A pharmaceutical composition according to  claim 1  wherein the protection is prophylactic.  
     
     
         6 . A pharmaceutical composition according to  claim 1  wherein the encoded recombinant antibody is derived from an antibody raised against the disease-causing agent.  
     
     
         7 . A pharmaceutical composition according to  claim 1  wherein the encoded antibody molecule comprises variable domains of immunoglobulin Heavy and Light chain genes linked together by a linker sequence.  
     
     
         8 . A pharmaceutical composition according to  claim 1 , wherein the nucleic acid construct further comprises a gene sequence encoding a secretion signal peptide.  
     
     
         9 . A pharmaceutical composition according to  claim 1  comprising genes encoding antibody molecules to several different epitopes of the disease-causing agent.  
     
     
         10 . A pharmaceutical composition according to  claim 1  comprising a gene-expression library encoding antibodies to the disease-causing agent.  
     
     
         11 . A pharmaceutical composition according to  claim 10  wherein the gene expression library encodes single-chain antibody molecules to the disease-causing agent.  
     
     
         12 . A pharmaceutical composition according to  claim 1  wherein the encoded recombinant antibody is a virus-neutralising antibody.  
     
     
         13 . A pharmaceutical composition according to  claim 12  wherein the encoded virus-neutralising antibody is single chain molecule.  
     
     
         14 . A pharmaceutical composition according to  claim 1  including a nucleic acid construct encoding a viral haemorrhagic septicaemia virus VHSV-neutralising monoclonal antibody 3F1H10 with two amino acids substituents in the H-chain gene respectively Asn 35a to Thr and Lys 64 to Thr and with the secretion signal of rainbow trout transforming growth factor (TGF-beta) added to the 5′ end of the gene.  
     
     
         15 . A pharmaceutical composition according to  claim 6  wherein when the disease-causing agent is an allergen the antibody molecule is derived from an antibody raised against IgE molecules.  
     
     
         16 . A pharmaceutical composition according to  claim 1  wherein the nucleic acid construct is formed from DNA.  
     
     
         17 . A pharmaceutical composition according to  claim 1  wherein the composition is in the form of a vaccine, dosage form, cream, ointment, liquid or paint.  
     
     
         18 . A pharmaceutical composition according to  claim 17  wherein the composition is for delivery by injection, spray or gene gun.  
     
     
         19 . A method of conferring protection against a disease caused by a pathogen, an allergen or a toxin on an animal comprising administering thereto a pharmaceutical composition of  claim 1 .  
     
     
         20 . (canceled)

Join the waitlist — get patent alerts

Track US2008085868A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.